Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

May 7, 2026 | Press Releases

Completion of Lead Clinical Candidate PH-762 Dose Escalation Trial for Treatment of Skin Cancer with Favorable Safety and Pathology DataKey Development Agreements Secured for Nonclinical Toxicology and U.S. cGMP Clinical Supply ManufacturingKing of Prussia,...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Apr 23, 2026 | Press Releases

Live Presentation and Q&A: Wednesday, April 29, 2026 12 PM EDTKing of Prussia, Pennsylvania–(Newsfile Corp. – April 23, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics...

Phio Pharmaceuticals Announces “Nobel Prize Winning Science Takes on Skin Cancer” in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026

Apr 13, 2026 | Press Releases

Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR. Todd Plott, M.D., Chief Medical Officer, Epiphany Dermatology will join Robert Bitterman, Phio Pharmaceuticals and Steven Saltzstein, Force Family...

Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026

Apr 9, 2026 | Press Releases

Investors and Advisors, and Life Sciences Analysts are Invited to Attend the New York City Event; Virtual Webcast Link Available BelowKing of Prussia, Pennsylvania–(Newsfile Corp. – April 9, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a...

Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762

Mar 30, 2026 | Press Releases

A Critical Next Step in Advancing Phio’s PH-762 Program to Treat Cutaneous CarcinomasKing of Prussia, Pennsylvania–(Newsfile Corp. – March 30, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company...

Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement

Mar 23, 2026 | Press Releases

Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March 28, 2026 at 3 PM (MDT)King of Prussia, Pennsylvania–(Newsfile Corp. – March 23, 2026) – Phio Pharmaceuticals Corp. (NASDAQ:...